CellMedics has developed BIOAVAILANT®, a proprietary, multi-patented, needle-free, cream-based drug-delivery platform engineered for proteins, antibodies, peptides, oligonucleotides, and other hard-to-deliver macromolecules traditionally limited to injection. Its coordinated, multi-mechanistic architecture addresses the interconnected challenges of cargo stability, biological-barrier transport, tissue localization, and cellular uptake—enabling targeted local, deep-tissue, ocular, or systemic delivery with enhanced bioavailability. CellMedics is applying BIOAVAILANT® across pain and inflammation, autoimmune and musculoskeletal diseases, dermatologic conditions, topical immunotherapy for skin cancer, metabolic disorders, and diseases affecting both the front and back of the eye. The platform is being advanced through candidate-specific pharmaceutical collaborations and strategic partnerships, alongside selected proprietary therapeutic programs.